Skip to search formSkip to main contentSkip to account menu

sorafenib

Known as: 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide, SFN 
A drug used to treat advanced kidney cancer and a type of liver cancer that cannot be removed by surgery. It is also being studied in the treatment… 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (4)

Antineoplastic AgentsNiacinamidePhenylurea CompoundsProtein Kinase Inhibitors
NCIt Antineoplastic Agent TerminologySorafenib:MCnc:Pt:Ser/Plas:Qnanalogs & derivativessorafenib 200 MG Oral Tablet [Nexavar]

Narrower (1)

Nexavar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial.
8592 Background: Tumor regressions have been observed in a significant proportion of advanced melanoma patients treated with… 
2010
2010
From a cancer drug fund to value based pricing of drugs
Such pricing may be hard to implement and may not add value 
2009
2009
Colon perforation during antiangiogenic therapy for malignant glioma.
Antiangiogenic drugs have emerged as effective treatment options for patients with recurrent malignant gliomas (MGs). Though this… 
2008
2008
Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: Impact on quality of life (QoL)
16122 Background: The MKIs sorafenib and sunitinib have shown a survival advantage in a variety of solid tumors. However, their… 
2008
2008
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium
5047 Background: Cediranib (AZD2171) is an oral highly potent, selective pan-VEGFR tyrosine kinase inhibitor expected to show… 
2008
2008
A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203)
4535 Background: Adenocarcinoma of the stomach and gastroesophageal junction (GEJ) is a highly virulent disease and remains a… 
2007
2007
Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307)
7707 Background: Systemic chemotherapy with cisplatin/pemetrexed is the approved first line treatment regimen for patients with… 
2007
2007
Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma
8511 Background: Sorafenib (SOR), a potent and selective multi-kinase inhibitor, exerts its anti-tumor and anti-angiogenic… 
2007
2007
SWOG 0514: A phase II study of sorafenib (BAY 43–9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas
4639 Background: There are no standard chemotherapeutic regimens for incurable biliary adenocarcinomas. Gemcitabine and… 
2001
2001
Broadband Multi Hop Networks with reduced Protocol Overhead
The BMBF founded project COVERAGE investigates broadband access to the IP core-net in public or semipublic hot spot scenarios for…